Tredegar Reports Fourth Quarter and Full Year 2024 Results
Fourth quarter 2024 net income (loss) from continuing operations was
Full year 2024 net income (loss) from continuing operations was
Fourth Quarter Financial Results Highlights
-
Earnings before interest, taxes, depreciation and amortization (“EBITDA”) from ongoing operations for
Aluminum Extrusions was$9.7 million in the fourth quarter of 2024 versus$8.0 million in the fourth quarter of 2023 and versus$6.2 million in the third quarter of 2024.- Sales volume was 35.8 million pounds in the fourth quarter of 2024 versus 32.9 million pounds in the fourth quarter of 2023.
- Net new orders, which remain low compared to pre-2020 historical levels, increased 23% in the fourth quarter of 2024 versus the fourth quarter of 2023 and 2% versus the third quarter of 2024. Open orders at the end of the fourth quarter of 2024 were approximately 17 million pounds versus 14 million pounds at the end of the fourth quarter of 2023 and versus 16 million pounds at the end of the third quarter of 2024.
-
EBITDA from ongoing operations for
PE Films was$7.6 million in the fourth quarter of 2024 versus$4.5 million in the fourth quarter of 2023 and versus$5.9 million in the third quarter of 2024.- Sales volume was 9.1 million pounds in the fourth quarter of 2024 versus 8.5 million pounds in the fourth quarter of 2023.
OPERATIONS REVIEW
|
|
Three Months Ended |
|
Favorable/ |
|
Year Ended |
|
Favorable/ |
||||||||||||||
(In thousands, except percentages) |
|
|
|
(Unfavorable) |
|
|
|
(Unfavorable) |
||||||||||||||
|
|
2024 |
|
|
|
2023 |
|
|
% Change |
|
|
2024 |
|
|
|
2023 |
|
|
% Change |
|||
Sales volume (lbs) |
|
|
35,849 |
|
|
|
32,940 |
|
|
8.8 |
% |
|
|
139,152 |
|
|
|
138,451 |
|
|
0.5 |
% |
Net sales |
|
$ |
122,462 |
|
|
$ |
110,196 |
|
|
11.1 |
% |
|
$ |
471,815 |
|
|
$ |
474,803 |
|
|
(0.6 |
)% |
Variable costs |
|
|
91,423 |
|
|
|
84,075 |
|
|
(8.7 |
)% |
|
|
354,397 |
|
|
|
365,320 |
|
|
3.0 |
% |
Last-in first-out inventory adjustment |
|
|
1,234 |
|
|
|
(944 |
) |
|
NM* |
|
|
|
1,234 |
|
|
|
(944 |
) |
|
NM* |
|
Manufacturing fixed costs1 |
|
|
10,364 |
|
|
|
10,146 |
|
|
(2.1 |
)% |
|
|
40,123 |
|
|
|
41,028 |
|
|
2.2 |
% |
Selling, general and administrative costs1 |
|
|
9,319 |
|
|
|
8,061 |
|
|
(15.6 |
)% |
|
|
33,638 |
|
|
|
29,725 |
|
|
(13.2 |
)% |
Other2 |
|
|
389 |
|
|
|
850 |
|
|
54.2 |
% |
|
|
1,066 |
|
|
|
1,698 |
|
|
37.2 |
% |
EBITDA from ongoing operations |
|
$ |
9,733 |
|
|
$ |
8,008 |
|
|
21.5 |
% |
|
$ |
41,357 |
|
|
$ |
37,976 |
|
|
8.9 |
% |
Depreciation & amortization |
|
|
(4,330 |
) |
|
|
(4,675 |
) |
|
7.4 |
% |
|
|
(17,722 |
) |
|
|
(17,927 |
) |
|
1.1 |
% |
EBIT from ongoing operations3 |
|
$ |
5,403 |
|
|
$ |
3,333 |
|
|
62.1 |
% |
|
$ |
23,635 |
|
|
$ |
20,049 |
|
|
17.9 |
% |
Capital expenditures |
|
$ |
5,635 |
|
|
$ |
2,477 |
|
|
|
|
$ |
10,097 |
|
|
$ |
20,339 |
|
|
|
||
1. Excludes related depreciation and amortization 2. Includes segment allocated employee compensation benefit expenses 3. For a reconciliation of this non-GAAP measure to the most directly comparable measure calculated in accordance with GAAP, see the EBITDA from ongoing operations by segment statements in the Financial Tables in this press release. *Not meaningful (“NM”) |
The following table presents the sales volume by end use market for the three months and years ended
|
|
Three Months Ended |
|
Favorable/ |
|
Three Months Ended |
|
Favorable/ |
|
Year Ended |
|
Favorable/ |
|||||||
(In millions of lbs) |
|
|
|
(Unfavorable) |
|
|
|
(Unfavorable) |
|
|
|
(Unfavorable) |
|||||||
|
2024 |
|
2023 |
|
% Change |
|
2024 |
|
% Change |
|
2024 |
|
2023 |
|
% Change |
||||
Sales volume by end-use market: |
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Non-residential B&C |
|
18.2 |
|
18.4 |
|
(1.1 |
)% |
|
18.7 |
|
(2.7 |
)% |
|
77.3 |
|
78.6 |
|
(1.7 |
)% |
Residential B&C |
|
2.4 |
|
2.0 |
|
20.0 |
% |
|
2.4 |
|
— |
% |
|
8.6 |
|
8.1 |
|
6.2 |
% |
Automotive |
|
2.6 |
|
3.3 |
|
(21.2 |
)% |
|
3.2 |
|
(18.8 |
)% |
|
12.0 |
|
13.8 |
|
(13.0 |
)% |
Specialty products |
|
12.6 |
|
9.2 |
|
37.0 |
% |
|
10.3 |
|
22.3 |
% |
|
41.3 |
|
38.0 |
|
8.7 |
% |
Total |
|
35.8 |
|
32.9 |
|
8.8 |
% |
|
34.6 |
|
3.5 |
% |
|
139.2 |
|
138.5 |
|
0.5 |
% |
Fourth Quarter 2024 Results vs. Fourth Quarter 2023 Results
Net sales (sales less freight) in the fourth quarter of 2024 increased 11.1% versus the fourth quarter of 2023 primarily due to higher sales volume and the pass-through of higher metal costs, partially offset by a lower average conversion price add-on to metal costs associated with a shift in sales mix. Sales volume in the fourth quarter of 2024 increased 8.8% versus the fourth quarter of 2023 and 3.5% versus the third quarter of 2024.
Net new orders increased 23% in the fourth quarter of 2024 versus the fourth quarter of 2023 and 2% versus the third quarter of 2024, largely due to improving sales opportunities. While net new orders continue to be below pre-pandemic levels, the fourth quarter of 2024 marked the ninth consecutive quarterly increase for this metric, supporting the Company’s belief that a steady recovery is underway.
Open orders at the end of the fourth quarter of 2024 were 17 million pounds, which is up from 16 million pounds at the end of the third quarter of 2024 and 14 million pounds at the end of the fourth quarter of 2023. This level is below the quarterly range of 21 to 27 million pounds in 2019 before pandemic-related disruptions that resulted in long lead times, driving a peak in open orders of approximately 100 million pounds during the first quarter of 2022.
The Company participated as a member of the
EBITDA from ongoing operations in the fourth quarter of 2024 increased
-
A
$4.9 million increase in contribution margin (net sales less variable costs) associated with:-
Higher volume (
$2.4 million ), increased labor productivity ($1.1 million ), and favorable variable manufacturing costs ($1.1 million ), partially offset by higher labor and employee-related costs ($0.7 million ), and lower spread (the difference between selling prices and metal costs) associated with a shift in sales mix ($1.6 million ); and -
The timing of the flow-through under the first-in first-out (“FIFO”) method of aluminum raw materials costs, which were previously acquired in a quickly changing commodity pricing environment, causing a temporary mismatch in the change in the cost of raw materials included in variable costs and the pass through to customers included in sales, resulted in a benefit of
$2.5 million in the fourth quarter of 2024 versus a charge of$0.2 million in the fourth quarter of 2023.
-
Higher volume (
-
Inventories accounted for under the last-in first-out (“LIFO”) method resulted in a charge of
$1.2 million in the fourth quarter of 2024 versus a benefit of$0.9 million in the fourth quarter of 2023; and -
Higher selling, general and administrative ("SG&A") expenses of
$1.3 million primarily associated with employee-related incentive compensation ($0.9 million ) and headquarters rent expenses ($0.1 million ).
Full Year 2024 Results vs. Full Year 2023 Results
Net sales in 2024 were relatively flat versus 2023 primarily due to flat sales volume and the pass-through of higher metal costs, partially offset by a lower average conversion price add-on to metal costs associated with a shift in sales mix.
EBITDA from ongoing operations increased
-
A
$7.9 million increase in contribution margin associated with:-
Favorable variable manufacturing costs (
$4.8 million ), higher labor productivity ($2.5 million ) and higher volume ($0.5 million ), partially offset by higher labor and employee-related costs ($2.2 million ) and lower spread associated with a shift in sales mix ($1.4 million ); and -
The timing of the flow-through under the FIFO method of aluminum raw material costs, which were previously acquired in a quickly changing commodity pricing environment, causing a temporary mismatch in the change in the cost of raw materials included in variable costs and the pass through to customers included in sales, resulted in a benefit of
$1.4 million in 2024 versus a charge of$1.0 million in 2023.
-
Favorable variable manufacturing costs (
-
Inventories accounted for under the LIFO method resulted in a charge of
$1.2 million in 2024 versus a benefit of$0.9 million in 2023; -
Lower manufacturing fixed costs of
$0.9 million primarily due to lower employee-related compensation and reduced outside services ($1.2 million ); and -
Higher SG&A expenses of
$3.9 million primarily due to employee-related incentive compensation ($2.7 million ) and headquarters rent expenses ($0.6 million ).
Goodwill Impairment at Bonnell
During the fourth quarter of 2024, the Company recognized a special item for the non-cash write-off of goodwill of
Projected Capital Expenditures and Depreciation & Amortization
Capital expenditures for
|
|
Three Months Ended |
|
Favorable/ |
|
Year Ended |
|
Favorable/ |
||||||||||||||
(In thousands, except percentages) |
|
|
|
(Unfavorable) |
|
|
|
(Unfavorable) |
||||||||||||||
|
|
2024 |
|
|
|
2023 |
|
|
% Change |
|
|
2024 |
|
|
|
2023 |
|
|
% Change |
|||
Sales volume (lbs) |
|
|
9,101 |
|
|
|
8,518 |
|
|
6.8 |
% |
|
|
39,324 |
|
|
|
29,355 |
|
|
34.0 |
% |
Net sales |
|
$ |
26,388 |
|
|
$ |
20,728 |
|
|
27.3 |
% |
|
$ |
105,199 |
|
|
$ |
76,763 |
|
|
37.0 |
% |
Variable costs |
|
|
12,767 |
|
|
|
11,213 |
|
|
(13.9 |
)% |
|
|
50,289 |
|
|
|
40,824 |
|
|
(23.2 |
)% |
LIFO inventory adjustment |
|
|
(174 |
) |
|
|
(1,333 |
) |
|
(86.9 |
)% |
|
|
(174 |
) |
|
|
(1,333 |
) |
|
(86.9 |
)% |
Manufacturing fixed costs1 |
|
|
3,416 |
|
|
|
3,626 |
|
|
5.8 |
% |
|
|
13,248 |
|
|
|
13,793 |
|
|
4.0 |
% |
Selling, general and administrative costs1 |
|
|
2,765 |
|
|
|
2,606 |
|
|
(6.1 |
)% |
|
|
11,245 |
|
|
|
12,106 |
|
|
7.1 |
% |
Other2 |
|
|
41 |
|
|
|
100 |
|
|
59.0 |
% |
|
|
105 |
|
|
|
156 |
|
|
32.7 |
% |
EBITDA from ongoing operations |
|
$ |
7,573 |
|
|
$ |
4,516 |
|
|
67.7 |
% |
|
$ |
30,486 |
|
|
$ |
11,217 |
|
|
171.8 |
% |
Depreciation & amortization |
|
|
(1,256 |
) |
|
|
(1,216 |
) |
|
(3.3 |
)% |
|
|
(5,200 |
) |
|
|
(6,522 |
) |
|
20.3 |
% |
EBIT from ongoing operations3 |
|
$ |
6,317 |
|
|
$ |
3,300 |
|
|
91.4 |
% |
|
$ |
25,286 |
|
|
$ |
4,695 |
|
|
NM* |
|
Capital expenditures |
|
$ |
634 |
|
|
$ |
266 |
|
|
|
|
$ |
1,761 |
|
|
$ |
1,772 |
|
|
|
||
1. Excludes related depreciation and amortization 2. Includes segment allocated employee compensation benefit expenses 3. For a reconciliation of this non-GAAP measure to the most directly comparable measure calculated in accordance with GAAP, see the EBITDA from ongoing operations by segment statements in the Financial Tables in this press release. *Not meaningful (“NM”) |
Fourth Quarter 2024 Results vs. Fourth Quarter 2023 Results
Net sales in the fourth quarter of 2024 increased 27.3% versus the fourth quarter of 2023, due to higher net sales in surface protection films. Surface Protection sales volume increased 43% in the fourth quarter of 2024 versus the fourth quarter of 2023. Although fourth quarter volume in Surface Protection is typically low due to seasonality, sales volume in the fourth quarter of 2024 increased 13% versus the third quarter of 2024. Surface Protection sales volume began to moderate as expected in the third quarter of 2024, following extremely high sales volume in the first half of 2024 associated with restocking of Surface Protection customer inventories. Overwrap sales volume in the fourth quarter of 2024 decreased 23% versus a strong volume performance in the fourth quarter of 2023.
EBITDA from ongoing operations in the fourth quarter of 2024 increased
-
Higher contribution margin of
$4.1 million resulting from:-
A
$4.0 million increase from Surface Protection associated with increased volume and favorable sales mix ($3.7 million ) and operating efficiencies and cost improvements ($0.3 million ); -
A
$0.3 million decrease from overwrap films primarily due to lower volume and unfavorable sales mix ($0.2 million ) and unfavorable pricing ($0.1 million ); and -
The pass-through lag associated with resin costs (no impact in the fourth quarter of 2024 versus a charge of
$0.3 million in the fourth quarter of 2023).
-
A
-
Inventories accounted for under the LIFO method that resulted in a benefit of
$0.2 million in the fourth quarter of 2024 versus a benefit of$1.3 million in the fourth quarter of 2023.
There have been significant cyclical swings in the sales volume and EBITDA from ongoing operations for
Full Year 2024 Results vs. Full Year 2023 Results
Net sales in 2024 increased 37.0% versus 2023 due to higher net sales in Surface Protection. Sales volume in 2024 for surface protection films increased 57% versus 2023, with extremely high sales volumes in the first half of 2024 associated with the restocking of Surface Protection customers’ inventories. Overwrap films volume increased 14% versus 2023, primarily due to volume increases associated with lower margin business.
EBITDA from ongoing operations in 2024 increased
-
Higher contribution margin of
$19.0 million resulting from:-
A
$19.4 million increase from Surface Protection associated with substantially higher volume and favorable pricing ($13.4 million ), and operating efficiencies and variable cost savings ($6.0 million ); -
Relatively flat contribution margin from overwrap films, associated with a shift in sales mix and unfavorable pricing (
$1.0 million ), offset by operating efficiencies and variable cost savings ($1.0 million ); and -
The pass-through lag associated with resin costs (
$1.0 million charge in 2024 versus a charge of$0.5 million in 2023).
-
A
-
Inventories accounted for under the LIFO method that resulted in a benefit of
$0.2 million in 2024 versus a benefit of$1.3 million in 2023. -
Lower SG&A of
$0.9 million primarily due to decreased research and development costs ($1.6 million ), partially offset by increased employee-related incentive compensation ($1.2 million ).
Refer to Item 7a. Quantitative and Qualitative Disclosures About Market Risk in the Form 10-K for additional information on resin price trends.
Projected Capital Expenditures and Depreciation & Amortization
Capital expenditures for
Corporate Expenses, Interest, Taxes and Other
Corporate expenses, net in 2024 decreased by
Interest expense was
The effective tax rate used to compute income taxes (benefit) from continuing operations in 2024 was (18.8)% compared to 34.1% in 2023. The change in effective tax rate was primarily due to pre-tax income in 2024 versus a pre-tax loss in 2023. The tax rate in 2023 was also significantly impacted by the release of stranded taxes upon termination of the pension plan. As of
On
Debt, Financial Leverage, Debt Covenants and Debt Refinancing
Total debt was
The Company has been focused on managing net working capital, capital expenditures and costs since a slowdown in business began in 2023. Total debt decreased
As of
FORWARD-LOOKING AND CAUTIONARY STATEMENTS
Some of the information contained in this press release may constitute “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. When the Company uses the words “believe,” “estimate,” “anticipate,” “appear to,” “expect,” “project,” “plan,” “likely,” “may” and similar expressions, it does so to identify forward-looking statements. Such statements are based on the Company's then current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those addressed in the forward-looking statements. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these forward-looking statements. Factors that could cause actual results to differ materially from expectations include, without limitation, the following:
- the impact of macroeconomic factors, such as inflation, interest rates and recession risks;
- an increase in the operating costs incurred by the Company’s business units, including, for example, the cost of raw materials and energy;
- noncompliance with any of the financial and other restrictive covenants in the ABL Facility;
- failure to continue to attract, develop and retain certain key officers or employees;
- disruptions to the Company’s manufacturing facilities, including those resulting from labor shortages;
- an information technology system failure or breach;
-
risks of doing business in countries outside the
U.S. that affect our international operations; - the impact of public health epidemics on employees, production and the global economy, such as the COVID-19 pandemic;
- political, economic and regulatory factors concerning the Company’s products;
- inability to develop, efficiently manufacture and deliver new products at competitive prices;
-
the impact of the imposition of tariffs and sanctions on imported aluminum ingot used by
Bonnell Aluminum ; - failure by governmental entities to prevent foreign companies from evading antidumping and countervailing duties;
- unanticipated problems or delays with the implementation of the enterprise resource planning and manufacturing executions systems, or security breaches and other disruptions to the Company's information technology infrastructure;
- loss of sales to significant customers on which the Company’s business is highly dependent;
- inability to achieve sales to new customers to replace lost business;
- failure of the Company’s customers to achieve success or maintain market share;
- failure to protect our intellectual property rights;
- inability to successfully complete strategic acquisitions or dispositions, failure to realize the expected benefits of such acquisitions or dispositions, and assumption of unanticipated risks in such acquisitions or dispositions;
and the other factors discussed in the reports Tredegar files with or furnishes to the
Tredegar does not undertake, and expressly disclaims any duty, to update any forward-looking statement made in this press release to reflect any change in management’s expectations or any change in conditions, assumptions or circumstances on which such statements are based, except as required by applicable law.
To the extent that the financial information portion of this press release contains non-GAAP financial measures, it also presents both the most directly comparable financial measures calculated and presented in accordance with GAAP and a quantitative reconciliation of the difference between any such non-GAAP measures and such comparable GAAP financial measures. Reconciliations of non-GAAP financial measures are provided in the Notes to the Financial Tables included with this press release and can also be found within “Presentations” in the “Investors” section of our website, www.tredegar.com.
Tredegar uses its website as a channel of distribution of material company information. Financial information and other material information regarding Tredegar is posted on and assembled in the “Investors” section of its website.
|
||||||||||||||||
Condensed Consolidated Statements of Income |
||||||||||||||||
(In Thousands, Except Per-Share Data) |
||||||||||||||||
(Unaudited) |
||||||||||||||||
|
|
|
|
|
||||||||||||
|
|
Three Months Ended |
|
Year Ended |
||||||||||||
|
|
|
|
|
||||||||||||
|
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
Sales |
|
$ |
154,049 |
|
|
$ |
136,167 |
|
|
$ |
598,025 |
|
|
$ |
573,323 |
|
Other income (expense), net (c)(d) |
|
|
(1,254 |
) |
|
|
(2,340 |
) |
|
|
(952 |
) |
|
|
(2,149 |
) |
|
|
|
152,795 |
|
|
|
133,827 |
|
|
|
597,073 |
|
|
|
571,174 |
|
|
|
|
|
|
|
|
|
|
||||||||
Cost of goods sold (c) |
|
|
124,367 |
|
|
|
112,530 |
|
|
|
480,958 |
|
|
|
480,440 |
|
Freight |
|
|
5,199 |
|
|
|
5,243 |
|
|
|
21,011 |
|
|
|
21,757 |
|
Selling, R&D and general expenses (c) |
|
|
18,967 |
|
|
|
17,549 |
|
|
|
73,681 |
|
|
|
68,282 |
|
Amortization of identifiable intangibles |
|
|
440 |
|
|
|
440 |
|
|
|
1,778 |
|
|
|
1,758 |
|
Pension and postretirement benefits |
|
|
54 |
|
|
|
890 |
|
|
|
217 |
|
|
|
10,844 |
|
Interest expense |
|
|
1,149 |
|
|
|
2,193 |
|
|
|
4,664 |
|
|
|
6,316 |
|
Asset impairments and costs associated with exit and disposal activities, net of adjustments (c) |
|
|
27 |
|
|
|
431 |
|
|
|
613 |
|
|
|
5,060 |
|
Pension settlement loss |
|
|
— |
|
|
|
66,679 |
|
|
|
— |
|
|
|
92,291 |
|
|
|
|
13,271 |
|
|
|
— |
|
|
|
13,271 |
|
|
|
34,891 |
|
|
|
|
163,474 |
|
|
|
205,955 |
|
|
|
596,193 |
|
|
|
721,639 |
|
Income (loss) from continuing operations before income taxes |
|
|
(10,679 |
) |
|
|
(72,128 |
) |
|
|
880 |
|
|
|
(150,465 |
) |
Income tax expense (benefit)(c) |
|
|
(3,340 |
) |
|
|
(38,071 |
) |
|
|
(165 |
) |
|
|
(51,300 |
) |
Net income (loss) from continuing operations |
|
|
(7,339 |
) |
|
|
(34,057 |
) |
|
|
1,045 |
|
|
|
(99,165 |
) |
Income (loss) from discontinued operations, net of tax |
|
|
(65,359 |
) |
|
|
(1,534 |
) |
|
|
(65,610 |
) |
|
|
(6,740 |
) |
Net income (loss) |
|
$ |
(72,698 |
) |
|
$ |
(35,591 |
) |
|
$ |
(64,565 |
) |
|
$ |
(105,905 |
) |
|
|
|
|
|
|
|
|
|
||||||||
Earnings (loss) per share: |
|
|
|
|
|
|
|
|
||||||||
Basic: |
|
|
|
|
|
|
|
|
||||||||
Continuing operations |
|
$ |
(0.21 |
) |
|
$ |
(1.00 |
) |
|
$ |
0.03 |
|
|
$ |
(2.91 |
) |
Discontinued operations |
|
|
(1.91 |
) |
|
|
(0.04 |
) |
|
|
(1.91 |
) |
|
|
(0.19 |
) |
Basic earnings (loss) per share |
|
$ |
(2.12 |
) |
|
$ |
(1.04 |
) |
|
$ |
(1.88 |
) |
|
$ |
(3.10 |
) |
Diluted: |
|
|
|
|
|
|
|
|
||||||||
Continuing operations |
|
$ |
(0.21 |
) |
|
$ |
(1.00 |
) |
|
$ |
0.03 |
|
|
$ |
(2.91 |
) |
Discontinued operations |
|
|
(1.91 |
) |
|
|
(0.04 |
) |
|
|
(1.91 |
) |
|
|
(0.19 |
) |
Diluted earnings (loss) per share |
|
$ |
(2.12 |
) |
|
$ |
(1.04 |
) |
|
$ |
(1.88 |
) |
|
$ |
(3.10 |
) |
|
|
|
|
|
|
|
|
|
||||||||
Shares used to compute earnings (loss) per share: |
|
|
|
|
|
|
|
|
||||||||
Basic |
|
|
34,293 |
|
|
|
34,289 |
|
|
|
34,346 |
|
|
|
34,133 |
|
Diluted |
|
|
34,293 |
|
|
|
34,289 |
|
|
|
34,346 |
|
|
|
34,133 |
|
|
||||||||||||||||
|
||||||||||||||||
(In Thousands) |
||||||||||||||||
(Unaudited) |
||||||||||||||||
|
|
|
|
|
||||||||||||
|
|
Three Months Ended |
|
Year Ended |
||||||||||||
|
|
|
|
|
||||||||||||
|
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
|
|
|
|
|
|
|
|
|
||||||||
|
|
$ |
122,462 |
|
|
$ |
110,196 |
|
|
$ |
471,815 |
|
|
$ |
474,803 |
|
|
|
|
26,388 |
|
|
|
20,728 |
|
|
|
105,199 |
|
|
|
76,763 |
|
Total net sales |
|
|
148,850 |
|
|
|
130,924 |
|
|
|
577,014 |
|
|
|
551,566 |
|
Add back freight |
|
|
5,199 |
|
|
|
5,243 |
|
|
|
21,011 |
|
|
|
21,757 |
|
Sales as shown in the condensed consolidated statements of income |
|
$ |
154,049 |
|
|
$ |
136,167 |
|
|
$ |
598,025 |
|
|
$ |
573,323 |
|
|
|
|
|
|
|
|
|
|
||||||||
EBITDA from Ongoing Operations (j) |
|
|
|
|
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
||||||||
Ongoing operations: |
|
|
|
|
|
|
|
|
||||||||
EBITDA (b) |
|
$ |
9,733 |
|
|
$ |
8,008 |
|
|
$ |
41,357 |
|
|
$ |
37,976 |
|
Depreciation & amortization |
|
|
(4,330 |
) |
|
|
(4,675 |
) |
|
|
(17,722 |
) |
|
|
(17,927 |
) |
EBIT (b) |
|
|
5,403 |
|
|
|
3,333 |
|
|
|
23,635 |
|
|
|
20,049 |
|
Plant shutdowns, asset impairments, restructurings and other (c) |
|
|
(360 |
) |
|
|
(1,736 |
) |
|
|
(5,346 |
) |
|
|
(3,557 |
) |
|
|
|
(13,271 |
) |
|
|
— |
|
|
|
(13,271 |
) |
|
|
— |
|
|
|
|
|
|
|
|
|
|
||||||||
Ongoing operations: |
|
|
|
|
|
|
|
|
||||||||
EBITDA (b) |
|
$ |
7,573 |
|
|
$ |
4,516 |
|
|
$ |
30,486 |
|
|
$ |
11,217 |
|
Depreciation & amortization |
|
|
(1,256 |
) |
|
|
(1,216 |
) |
|
|
(5,200 |
) |
|
|
(6,522 |
) |
EBIT (b) |
|
|
6,317 |
|
|
|
3,300 |
|
|
|
25,286 |
|
|
|
4,695 |
|
Plant shutdowns, asset impairments, restructurings and other (c) |
|
|
165 |
|
|
|
(408 |
) |
|
|
(420 |
) |
|
|
(4,972 |
) |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(34,891 |
) |
Total |
|
|
(1,746 |
) |
|
|
4,489 |
|
|
|
29,884 |
|
|
|
(18,676 |
) |
Interest income |
|
|
5 |
|
|
|
403 |
|
|
|
36 |
|
|
|
514 |
|
Interest expense |
|
|
1,149 |
|
|
|
2,193 |
|
|
|
4,664 |
|
|
|
6,316 |
|
Gain on investment in kaleo, Inc. (d) |
|
|
— |
|
|
|
— |
|
|
|
144 |
|
|
|
262 |
|
Stock option-based compensation costs |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
231 |
|
Pension settlement loss |
|
|
— |
|
|
|
66,679 |
|
|
|
— |
|
|
|
92,291 |
|
Corporate expenses, net (c) |
|
|
7,789 |
|
|
|
8,148 |
|
|
|
24,520 |
|
|
|
33,727 |
|
Income (loss) from continuing operations before income taxes |
|
|
(10,679 |
) |
|
|
(72,128 |
) |
|
|
880 |
|
|
|
(150,465 |
) |
Income tax expense (benefit) |
|
|
(3,340 |
) |
|
|
(38,071 |
) |
|
|
(165 |
) |
|
|
(51,300 |
) |
Net income (loss) from continuing operations |
|
|
(7,339 |
) |
|
|
(34,057 |
) |
|
|
1,045 |
|
|
|
(99,165 |
) |
Income (loss) from discontinued operations, net of tax |
|
|
(65,359 |
) |
|
|
(1,534 |
) |
|
|
(65,610 |
) |
|
|
(6,740 |
) |
Net income (loss) |
|
$ |
(72,698 |
) |
|
$ |
(35,591 |
) |
|
$ |
(64,565 |
) |
|
$ |
(105,905 |
) |
|
||||||
Condensed Consolidated Balance Sheets |
||||||
(In Thousands) |
||||||
(Unaudited) |
||||||
|
|
|
|
|
||
|
|
|
|
|
||
Assets |
|
|
|
|
||
Cash & cash equivalents |
|
$ |
7,062 |
|
$ |
9,660 |
Restricted cash |
|
|
— |
|
|
3,391 |
Accounts & other receivables, net |
|
|
64,817 |
|
|
55,615 |
Income taxes recoverable |
|
|
— |
|
|
1,182 |
Inventories |
|
|
51,381 |
|
|
49,654 |
Prepaid expenses & other |
|
|
16,567 |
|
|
8,817 |
Current assets of discontinued operations |
|
|
— |
|
|
48,358 |
Total current assets |
|
|
139,827 |
|
|
176,677 |
Property, plant & equipment, net |
|
|
137,032 |
|
|
151,157 |
Right-of-use leased assets |
|
|
14,635 |
|
|
11,100 |
Identifiable intangible assets, net |
|
|
7,326 |
|
|
9,105 |
|
|
|
22,446 |
|
|
35,717 |
Deferred income taxes |
|
|
32,517 |
|
|
23,155 |
Other assets |
|
|
2,448 |
|
|
3,442 |
Non-current assets of discontinued operations |
|
|
126 |
|
|
36,108 |
Total assets |
|
$ |
356,357 |
|
$ |
446,461 |
Liabilities and Shareholders’ Equity |
|
|
|
|
||
Accounts payable |
|
$ |
64,704 |
|
$ |
69,328 |
Accrued expenses |
|
|
22,168 |
|
|
18,606 |
Lease liability, short-term |
|
|
2,453 |
|
|
1,903 |
Short-term debt |
|
|
1,322 |
|
|
— |
ABL revolving facility (i) |
|
|
— |
|
|
126,322 |
Income taxes payable |
|
|
320 |
|
|
183 |
Current liabilities of discontinued operations |
|
|
741 |
|
|
32,762 |
Total current liabilities |
|
|
91,708 |
|
|
249,104 |
Lease liability, long-term |
|
|
12,993 |
|
|
10,396 |
ABL revolving facility (i) |
|
|
60,600 |
|
|
— |
Pension and other postretirement benefit obligations, net |
|
|
5,914 |
|
|
6,643 |
Deferred income taxes |
|
|
69 |
|
|
— |
Other non-current liabilities |
|
|
4,105 |
|
|
3,862 |
Non-current assets of discontinued operations |
|
|
— |
|
|
20,803 |
Shareholders’ equity |
|
|
180,968 |
|
|
155,653 |
Total liabilities and shareholders’ equity |
|
$ |
356,357 |
|
$ |
446,461 |
|
||||||||
Condensed Consolidated Statements of Cash Flows |
||||||||
(In Thousands) |
||||||||
(Unaudited) |
||||||||
|
|
|
||||||
|
|
Year Ended |
||||||
|
|
|
2024 |
|
|
|
2023 |
|
Cash flows from operating activities: |
|
|
|
|
||||
Net income (loss) |
|
$ |
(64,565 |
) |
|
$ |
(105,905 |
) |
Adjustments for noncash items: |
|
|
|
|
||||
Depreciation |
|
|
23,681 |
|
|
|
25,786 |
|
Amortization of intangibles |
|
|
1,856 |
|
|
|
1,897 |
|
Reduction of right-of-use assets |
|
|
2,259 |
|
|
|
2,220 |
|
|
|
|
13,271 |
|
|
|
34,891 |
|
Deferred income taxes |
|
|
(8,202 |
) |
|
|
(56,098 |
) |
Accrued pension and postretirement benefits |
|
|
217 |
|
|
|
10,844 |
|
Pension settlement loss |
|
|
— |
|
|
|
92,291 |
|
Stock-based compensation expense |
|
|
2,498 |
|
|
|
1,978 |
|
Loss on sale of divested business |
|
|
74,877 |
|
|
|
— |
|
Gain on investment in kaléo |
|
|
(144 |
) |
|
|
(262 |
) |
Impairment of |
|
|
— |
|
|
|
3,454 |
|
Changes in assets and liabilities: |
|
|
|
|
||||
Accounts and other receivables |
|
|
(14,785 |
) |
|
|
17,400 |
|
Inventories |
|
|
(6,911 |
) |
|
|
47,607 |
|
Income taxes recoverable/payable |
|
|
137 |
|
|
|
(406 |
) |
Prepaid expenses and other |
|
|
(7,174 |
) |
|
|
1,204 |
|
Accounts payable and accrued expenses |
|
|
10,009 |
|
|
|
(25,165 |
) |
Lease liability |
|
|
(2,749 |
) |
|
|
(2,299 |
) |
Pension and postretirement benefit plan contributions |
|
|
(587 |
) |
|
|
(28,269 |
) |
Other, net |
|
|
1,820 |
|
|
|
2,827 |
|
Net cash provided by (used in) operating activities |
|
|
25,508 |
|
|
|
23,995 |
|
Cash flows from investing activities: |
|
|
|
|
||||
Capital expenditures |
|
|
(14,347 |
) |
|
|
(26,446 |
) |
Proceeds on sale of investment in kaléo |
|
|
144 |
|
|
|
262 |
|
Net proceeds on sale of divested business (net of |
|
|
54,631 |
|
|
|
— |
|
Proceeds from the sale of assets |
|
|
83 |
|
|
|
— |
|
Net cash provided by (used in) investing activities |
|
|
40,511 |
|
|
|
(26,184 |
) |
Cash flows from financing activities: |
|
|
|
|
||||
Borrowings |
|
|
615,201 |
|
|
|
116,134 |
|
Debt principal payments |
|
|
(679,590 |
) |
|
|
(107,713 |
) |
Dividends paid |
|
|
— |
|
|
|
(8,884 |
) |
Debt financing fees |
|
|
(587 |
) |
|
|
(4,021 |
) |
Net cash provided by (used in) financing activities |
|
|
(64,976 |
) |
|
|
(4,484 |
) |
Effect of exchange rate changes on cash |
|
|
(7,436 |
) |
|
|
896 |
|
Increase (decrease) in cash, cash equivalents and restricted cash |
|
|
(6,393 |
) |
|
|
(5,777 |
) |
Cash, cash equivalents and restricted cash at beginning of period |
|
|
13,455 |
|
|
|
19,232 |
|
Cash, cash equivalents and restricted cash at end of period |
|
$ |
7,062 |
|
|
$ |
13,455 |
|
Notes to the Financial Tables |
|
(Unaudited) |
|
(a) |
Tredegar’s presentation of net income (loss) and diluted earnings (loss) per share from ongoing operations are non-GAAP financial measures that exclude the effects of gains or losses associated with plant shutdowns, asset impairments and restructurings, gains or losses from the sale of assets, goodwill impairment charges, discontinued operations, net periodic benefit cost for the frozen defined benefit pension plan prior to termination and other items (which includes gains and losses for an investment accounted for under the fair value method) which have been presented separately and removed from net income (loss) from continuing operations and diluted earnings (loss) per share as reported under GAAP. Net income (loss) and diluted earnings (loss) per share from ongoing operations are key financial and analytical measures used by management to gauge the operating performance of Tredegar’s ongoing operations. They are not intended to represent the stand-alone results for Tredegar’s ongoing operations under GAAP and should not be considered as an alternative to net income (loss) from continuing operations or earnings (loss) per share as defined by GAAP. They exclude items that management believes do not relate to Tredegar’s ongoing operations. A reconciliation to net income (loss) and diluted earnings (loss) per share from ongoing operations for the three months and the years ended |
|
|
Three Months Ended |
|
Year Ended |
||||||||||||
(In millions, except per share data) |
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
Net income (loss) from continuing operations as reported under GAAP1 |
|
$ |
(7.3 |
) |
|
$ |
(34.1 |
) |
|
$ |
1.0 |
|
|
$ |
(99.2 |
) |
After-tax effects of: |
|
|
|
|
|
|
|
|
||||||||
(Gains) losses associated with plant shutdowns, asset impairments and restructurings |
|
|
(0.1 |
) |
|
|
0.3 |
|
|
|
0.4 |
|
|
|
4.0 |
|
(Gains) losses from sale of assets and other: |
|
|
|
|
|
|
|
|
||||||||
Gain associated with the investment in kaléo |
|
|
— |
|
|
|
— |
|
|
|
(0.1 |
) |
|
|
(0.2 |
) |
Valuation allowance reversal on existing deferred tax assets as a result of the sale of Terphane |
|
|
(2.5 |
) |
|
|
— |
|
|
|
(0.7 |
) |
|
|
— |
|
Tax expense (benefit) from adjustments to deferred income tax liabilities under new |
|
|
— |
|
|
|
(0.2 |
) |
|
|
— |
|
|
|
1.3 |
|
Group annuity contract premium expense2 |
|
|
— |
|
|
|
1.6 |
|
|
|
(0.2 |
) |
|
|
1.6 |
|
Other |
|
|
1.5 |
|
|
|
1.8 |
|
|
|
6.4 |
|
|
|
4.1 |
|
Net periodic benefit cost for the frozen defined benefit pension plan prior to termination2 |
|
|
— |
|
|
|
0.7 |
|
|
|
— |
|
|
|
8.4 |
|
Pension settlement loss2 |
|
|
— |
|
|
|
31.0 |
|
|
|
— |
|
|
|
51.0 |
|
|
|
|
10.4 |
|
|
|
— |
|
|
|
10.4 |
|
|
|
27.0 |
|
Net income (loss) from ongoing operations1 |
|
$ |
2.0 |
|
|
$ |
1.1 |
|
|
$ |
17.2 |
|
|
$ |
(2.0 |
) |
|
|
|
|
|
|
|
|
|
||||||||
Earnings (loss) from continuing operations per share as reported under GAAP (diluted) |
|
$ |
(0.21 |
) |
|
$ |
(1.00 |
) |
|
$ |
0.03 |
|
|
$ |
(2.91 |
) |
After-tax effects per diluted share of: |
|
|
|
|
|
|
|
|
||||||||
(Gains) losses associated with plant shutdowns, asset impairments and restructurings |
|
|
— |
|
|
|
0.01 |
|
|
|
0.01 |
|
|
|
0.12 |
|
(Gains) losses from sale of assets and other: |
|
|
|
|
|
|
|
|
||||||||
Gain associated with the investment in kaléo |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(0.01 |
) |
Valuation allowance reversal on existing deferred tax assets as a result of the sale of Terphane |
|
|
(0.07 |
) |
|
|
— |
|
|
|
(0.02 |
) |
|
|
— |
|
Tax expense (benefit) from adjustments to deferred income tax liabilities under new |
|
|
— |
|
|
|
(0.01 |
) |
|
|
— |
|
|
|
0.04 |
|
Group annuity contract premium expense2 |
|
|
— |
|
|
|
0.05 |
|
|
|
— |
|
|
|
0.05 |
|
Other |
|
|
0.04 |
|
|
|
0.06 |
|
|
|
0.18 |
|
|
|
0.12 |
|
Net periodic benefit cost for the frozen defined benefit pension plan prior to termination2 |
|
|
— |
|
|
|
0.02 |
|
|
|
— |
|
|
|
0.25 |
|
Pension settlement loss2 |
|
|
— |
|
|
|
0.90 |
|
|
|
— |
|
|
|
1.48 |
|
|
|
|
0.30 |
|
|
|
— |
|
|
|
0.30 |
|
|
|
0.79 |
|
Earnings (loss) per share from ongoing operations (diluted) |
|
$ |
0.06 |
|
|
$ |
0.03 |
|
|
$ |
0.50 |
|
|
$ |
(0.07 |
) |
1. Reconciliations of the pre-tax and post-tax balances attributed to net income (loss) are shown in Note (e). 2. For more information, see Note (h). 3. For more information, see the “Goodwill Impairment at Bonnell” section above. 4. For more information, see Note (g). |
(b) |
EBITDA (earnings before interest, taxes, depreciation and amortization) from ongoing operations is the key segment profitability metric used by the Company’s chief operating decision maker (“CODM”) to assess segment financial performance. The Company uses sales less freight (“net sales”) as its measure of revenues from external customers at the segment level. For more business segment information, see Note 12. Business Segments to the Consolidated Financial Statements included in Item 15 of the Form 10-K. |
|
|
|
EBIT (earnings before interest and taxes) from ongoing operations is a non-GAAP financial measure included in the accompanying tables and the reconciliation of segment financial information to consolidated results for the Company in the net sales and EBITDA from ongoing operations by segment statements. It is not intended to represent the stand-alone results for Tredegar’s ongoing operations under GAAP and should not be considered as an alternative to net income (loss) as defined by GAAP. The Company believes that EBIT is a widely understood and utilized metric that is meaningful to certain investors and that including this financial metric in the reconciliation of management’s performance metric, EBITDA from ongoing operations, provides useful information to those investors that primarily utilize EBIT to analyze the Company’s core operations. |
|
|
(c) |
Gains and losses associated with plant shutdowns, asset impairments, restructurings and other items for the three months and the years ended |
|
Three Months Ended |
Year Ended |
||||||||||
(In millions) |
Pre-Tax |
Net of Tax |
Pre-Tax |
Net of Tax |
||||||||
|
|
|
|
|
||||||||
(Gains) losses associated with plant shutdowns, asset impairments and restructurings: |
|
|
|
|
||||||||
Production equipment asset impairment |
$ |
0.2 |
|
$ |
0.1 |
|
$ |
0.2 |
|
$ |
0.1 |
|
(Gains) losses from sale of assets, investment writedowns and other items: |
|
|
|
|
||||||||
Consulting expenses for ERP/MES project1 |
|
0.5 |
|
|
0.3 |
|
|
2.6 |
|
|
1.9 |
|
Storm damage to the |
|
(0.7 |
) |
|
(0.5 |
) |
|
(0.4 |
) |
|
(0.3 |
) |
Legal fees associated with the Aluminum Extruders Trade Case and other matters1 |
|
0.3 |
|
|
0.2 |
|
|
1.2 |
|
|
0.9 |
|
Resolution of customer quality complaint4 |
|
(0.1 |
) |
|
— |
|
|
0.7 |
|
|
0.6 |
|
|
|
13.3 |
|
|
10.4 |
|
|
13.3 |
|
|
10.4 |
|
Total for |
$ |
13.5 |
|
$ |
10.5 |
|
$ |
17.6 |
|
$ |
13.6 |
|
|
|
|
|
|
||||||||
(Gains) losses associated with plant shutdowns, asset impairments and restructurings: |
|
|
|
|
||||||||
|
$ |
(0.1 |
) |
$ |
(0.1 |
) |
$ |
0.2 |
|
$ |
0.1 |
|
|
|
(0.1 |
) |
|
(0.1 |
) |
|
0.2 |
|
|
0.2 |
|
Total for |
$ |
(0.2 |
) |
$ |
(0.2 |
) |
$ |
0.4 |
|
$ |
0.3 |
|
Corporate: |
|
|
|
|
||||||||
(Gain) losses from sale of assets, investment writedowns and other items: |
|
|
|
|
||||||||
Professional fees associated with business development activities1 |
$ |
0.3 |
|
$ |
0.3 |
|
$ |
0.6 |
|
$ |
0.7 |
|
Professional fees associated with remediation activities related to internal control over financial reporting1 |
|
0.2 |
|
|
0.1 |
|
|
1.8 |
|
|
1.3 |
|
Professional fees associated with the transition to the ABL Facility1 |
|
0.1 |
|
|
0.1 |
|
|
0.4 |
|
|
0.3 |
|
Deferred and discretionary incentive payments made subsequent to the sale of Terphane2 |
|
1.3 |
|
|
1.0 |
|
|
1.3 |
|
|
1.0 |
|
Valuation allowance reversal on existing deferred tax assets as a result of the sale of Terphane3 |
|
— |
|
|
(2.5 |
) |
|
— |
|
|
(0.7 |
) |
Group annuity contract premium adjustment2,6 |
|
(0.1 |
) |
|
— |
|
|
(0.3 |
) |
|
(0.2 |
) |
Total for Corporate |
$ |
1.8 |
|
$ |
(1.0 |
) |
$ |
3.8 |
|
$ |
2.4 |
|
1. Included in “Selling, R&D and general expenses” in the condensed consolidated statements of income. 2. Included in “Other income (expense), net” in the condensed consolidated statements of income. 3. Included in “Income tax expense (benefit)” in the condensed consolidated statements of income. 4. Included in “Sales” in the condensed consolidated statements of income. 5. For more information, see Note (k) 6. For more information, see Note (h). 7. For more information, see the “Goodwill Impairment at Bonnell” section above. |
|
Three Months Ended |
Year Ended |
||||||||||
(In millions) |
Pre-Tax |
Net of Tax |
Pre-Tax |
Net of Tax |
||||||||
|
|
|
|
|
||||||||
(Gains) losses associated with plant shutdowns, asset impairments and restructurings: |
|
|
|
|
||||||||
Other restructuring costs - severance |
$ |
— |
|
$ |
— |
|
$ |
0.1 |
|
$ |
0.1 |
|
(Gains) losses from sale of assets, investment writedowns and other items: |
|
|
|
|
||||||||
Consulting expenses for ERP/MES project1 |
|
0.6 |
|
|
0.5 |
|
|
1.8 |
|
|
1.4 |
|
Storm damage to the |
|
— |
|
|
— |
|
|
0.5 |
|
|
0.4 |
|
Legal fees associated with the Aluminum Extruders Trade Case1 |
|
0.5 |
|
|
0.4 |
|
|
0.5 |
|
|
0.4 |
|
Total for |
$ |
1.1 |
|
$ |
0.9 |
|
$ |
2.9 |
|
$ |
2.3 |
|
|
|
|
|
|
||||||||
(Gains) losses associated with plant shutdowns, asset impairments and restructurings: |
|
|
|
|
||||||||
Impairment of |
$ |
0.1 |
|
$ |
0.1 |
|
$ |
3.5 |
|
$ |
2.7 |
|
|
|
0.1 |
|
|
0.1 |
|
|
1.3 |
|
|
1.0 |
|
|
|
0.3 |
|
|
0.2 |
|
|
0.3 |
|
|
0.2 |
|
|
|
(0.1 |
) |
|
(0.1 |
) |
|
(0.1 |
) |
|
(0.1 |
) |
|
|
— |
|
|
— |
|
|
34.9 |
|
|
27.0 |
|
Total for |
$ |
0.4 |
|
$ |
0.3 |
|
$ |
39.9 |
|
$ |
30.8 |
|
Corporate: |
|
|
|
|
||||||||
(Gain) losses from sale of assets, investment writedowns and other items: |
|
|
|
|
||||||||
Professional fees associated with business development activities1 |
$ |
0.3 |
|
$ |
0.3 |
|
$ |
0.2 |
|
$ |
0.2 |
|
Professional fees associated with remediation activities related to internal control over financial reporting1 |
|
0.8 |
|
|
0.6 |
|
|
2.0 |
|
|
1.6 |
|
Write-down of investment in |
|
— |
|
|
— |
|
|
0.2 |
|
|
0.1 |
|
Tax expense from adjustment to deferred income tax liabilities under new |
|
— |
|
|
(0.2 |
) |
|
— |
|
|
1.3 |
|
Group annuity contract premium expense2,6 |
|
2.0 |
|
|
1.6 |
|
|
2.0 |
|
|
1.6 |
|
Net periodic benefit cost for the frozen defined benefit pension plan prior to termination6 |
|
0.9 |
|
|
0.7 |
|
|
10.8 |
|
|
8.4 |
|
Pension settlement loss6 |
|
66.7 |
|
|
31.0 |
|
|
92.3 |
|
|
51.0 |
|
Total for Corporate |
$ |
70.7 |
|
$ |
34.0 |
|
$ |
107.5 |
|
$ |
64.2 |
|
1. Included in “Selling, R&D and general expenses” in the condensed consolidated statements of income. 2. Included in “Other income (expense), net” in the condensed consolidated statements of income. 3. Included in “Income tax expense (benefit)” in the condensed consolidated statements of income. 4. For more information, see Note (k). 5. For more information, see Note (g). 6. For more information, see Note (h). |
(d) |
On |
(e) |
For discussion on Tredegar’s presentation of net income (loss) from ongoing operations, please refer to Note (a) above. Reconciliations of the pre-tax and post-tax balances attributed to net income (loss) from ongoing operations for the three months and the years ended |
(In millions) |
Pre-Tax |
|
Taxes Expense (Benefit) |
|
After-Tax |
|
Effective Tax Rate |
|||||||
Three Months Ended |
(a) |
|
(b) |
|
|
|
(b)/(a) |
|||||||
Net income (loss) from continuing operations as reported under GAAP |
$ |
(10.7 |
) |
|
$ |
(3.4 |
) |
|
$ |
(7.3 |
) |
|
31.8 |
% |
(Gains) losses associated with plant shutdowns, asset impairments and restructurings |
|
— |
|
|
|
0.1 |
|
|
|
(0.1 |
) |
|
|
|
(Gains) losses from sale of assets and other |
|
1.8 |
|
|
|
2.8 |
|
|
|
(1.0 |
) |
|
|
|
|
|
13.3 |
|
|
|
2.9 |
|
|
|
10.4 |
|
|
|
|
Net income (loss) from ongoing operations |
$ |
4.4 |
|
|
$ |
2.4 |
|
|
$ |
2.0 |
|
|
56.0 |
% |
Three Months Ended |
|
|
|
|
|
|
|
|||||||
Net income (loss) from continuing operations as reported under GAAP |
$ |
(72.1 |
) |
|
$ |
(38.0 |
) |
|
$ |
(34.1 |
) |
|
52.7 |
% |
(Gains) losses associated with plant shutdowns, asset impairments and restructurings |
|
0.4 |
|
|
|
0.1 |
|
|
|
0.3 |
|
|
|
|
(Gains) losses from sale of assets and other |
|
4.2 |
|
|
|
1.0 |
|
|
|
3.2 |
|
|
|
|
Net periodic benefit cost for the frozen defined benefit pension plan in process of termination |
|
0.9 |
|
|
|
0.2 |
|
|
|
0.7 |
|
|
|
|
Pension settlement loss |
|
66.7 |
|
|
|
35.7 |
|
|
|
31.0 |
|
|
|
|
Net income (loss) from ongoing operations |
$ |
0.1 |
|
|
$ |
(1.0 |
) |
|
$ |
1.1 |
|
|
NM* |
|
Year Ended |
|
|
|
|
|
|
|
|||||||
Net income (loss) from continuing operations as reported under GAAP |
$ |
0.9 |
|
|
$ |
(0.1 |
) |
|
$ |
1.0 |
|
|
(18.8 |
)% |
(Gains) losses associated with plant shutdowns, asset impairments and restructurings |
|
0.6 |
|
|
|
0.2 |
|
|
|
0.4 |
|
|
|
|
(Gains) losses from sale of assets and other |
|
7.8 |
|
|
|
2.4 |
|
|
|
5.4 |
|
|
|
|
|
|
13.3 |
|
|
|
2.9 |
|
|
|
10.4 |
|
|
|
|
Net income (loss) from ongoing operations |
$ |
22.6 |
|
|
$ |
5.4 |
|
|
$ |
17.2 |
|
|
23.8 |
% |
Year Ended |
|
|
|
|
|
|
|
|||||||
Net income (loss) continuing operations as reported under GAAP |
$ |
(150.5 |
) |
|
$ |
(51.3 |
) |
|
$ |
(99.2 |
) |
|
34.1 |
% |
(Gains) losses associated with plant shutdowns, asset impairments and restructurings |
|
5.1 |
|
|
|
1.1 |
|
|
|
4.0 |
|
|
|
|
(Gains) losses from sale of assets and other |
|
6.9 |
|
|
|
0.1 |
|
|
|
6.8 |
|
|
|
|
Net periodic benefit cost for the frozen defined benefit pension plan in process of termination |
|
10.8 |
|
|
|
2.4 |
|
|
|
8.4 |
|
|
|
|
Pension settlement loss |
|
92.3 |
|
|
|
41.3 |
|
|
|
51.0 |
|
|
|
|
|
|
34.9 |
|
|
|
7.9 |
|
|
|
27.0 |
|
|
|
|
Net income (loss) from ongoing operations |
$ |
(0.5 |
) |
|
$ |
1.5 |
|
|
$ |
(2.0 |
) |
|
NM* |
|
* Not meaningful (“NM”) |
(f) Net debt is calculated as follows: |
||||||
(In millions) |
|
|
|
|
||
|
2024 |
|
2023 |
|||
Short-term debt |
|
$ |
1.3 |
|
$ |
— |
ABL revolving facility (i) |
|
|
60.6 |
|
|
126.3 |
Total debt |
|
|
61.9 |
|
|
126.3 |
Less: Cash and cash equivalents |
|
|
7.1 |
|
|
9.7 |
Less: Restricted cash |
|
|
— |
|
|
3.4 |
Net debt |
|
$ |
54.8 |
|
$ |
113.2 |
As of
Net leverage ratio is a non-GAAP financial measure. It is not intended to represent the stand-alone results for Tredegar under GAAP and should not be considered as an alternative to net income (loss) and total debt as defined by GAAP. Net leverage ratio is utilized by management in evaluating the Company’s financial leverage, and management believes that investors also may find the net leverage ratio to be helpful for the same purposes. In addition, earnings before interest, taxes, depreciation and amortization as defined in the ABL Facility ("Credit EBITDA") is provided below.
|
As of or for Twelve Months Ended |
|
As of or for Twelve Months Ended |
||
($ in millions) |
|
||||
Net debt |
$ |
54.8 |
|
$ |
113.2 |
Credit EBITDA(2) |
$ |
51.1 |
|
$ |
30.4 |
Net leverage ratio |
|
1.1 |
|
|
3.7 |
1. Actual Credit EBITDA amounts are for the twelve months ended 2. See Note (l) for more information. |
(g) |
During 2023, uncertainty about the timing of a recovery in the consumer electronics market persisted, and manufacturers in the supply chain for consumer electronics continued to experience reduced capacity utilization and inventory corrections. In light of the limited visibility on the timing of a recovery and the expected adverse future impact to the Surface Protection business, coupled with a cautious outlook on new product development opportunities, the Company performed a Step 1 goodwill impairment analysis, as of |
|
|
(h) |
During the third quarter of 2023, the Company remeasured the pension plan, which resulted in a pre-tax pension settlement loss in the condensed consolidated results of operation of |
|
|
(i) |
The ABL Facility has customary representations and warranties including, as a condition to each borrowing, that all such representations and warranties are true and correct in all material respects (including a representation that no Material Adverse Effect (as defined in the ABL Facility) has occurred since |
|
|
|
In accordance with the ABL Facility, the lenders have been provided with the Company’s financial statements, covenant compliance certificates and projections to facilitate their ongoing assessment of the Company. Accordingly, the Company believes the likelihood that lenders would exercise the subjective acceleration clause whereby prohibiting future borrowings is remote. As of |
|
|
(j) |
Tredegar’s presentation of Consolidated EBITDA from ongoing operations is a non-GAAP financial measure that excludes the effects of gains or losses associated with plant shutdowns, asset impairments and restructurings, gains or losses from the sale of assets, goodwill impairment charges, discontinued operations, net periodic benefit cost for the frozen defined benefit pension plan and other items (which includes gains and losses for an investment accounted for under the fair value method). Consolidated EBITDA from ongoing operations also excludes depreciation & amortization, stock option-based compensation costs, interest and income taxes. Consolidated EBITDA is a key financial and analytical measure used by management to gauge the operating performance of Tredegar’s ongoing operations. It is not intended to represent the stand-alone results for Tredegar’s ongoing operations under GAAP and should not be considered as an alternative to net income (loss) or earnings (loss) per share as defined by GAAP. It excludes items that management believes do not relate to Tredegar’s ongoing operations. A reconciliation of Consolidated EBITDA from ongoing operations for the three months and the years ended |
|
Three Months Ended |
|
Year Ended |
||||||||||||
($ in millions) |
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
Net income (loss) from continuing operations as reported under GAAP1 |
$ |
(7.3 |
) |
|
$ |
(34.1 |
) |
|
$ |
1.0 |
|
|
$ |
(99.2 |
) |
After-tax effects of: |
|
|
|
|
|
|
|
||||||||
(Gains) losses associated with plant shutdowns, asset impairments and restructurings |
|
(0.1 |
) |
|
|
0.3 |
|
|
|
0.4 |
|
|
|
4.0 |
|
Gain associated with the investment in kaléo |
|
— |
|
|
|
— |
|
|
|
(0.1 |
) |
|
|
(0.2 |
) |
(Gains) losses from sale of assets and other |
|
1.5 |
|
|
|
1.8 |
|
|
|
6.4 |
|
|
|
4.1 |
|
Tax expense (benefit) from adjustments to deferred income tax liabilities under new |
|
— |
|
|
|
(0.2 |
) |
|
|
— |
|
|
|
1.3 |
|
Group annuity contract premium expense2 |
|
— |
|
|
|
1.6 |
|
|
|
(0.2 |
) |
|
|
1.6 |
|
Valuation allowance reversal on existing deferred tax assets as a result of the sale of Terphane |
|
(2.5 |
) |
|
|
— |
|
|
|
(0.7 |
) |
|
|
— |
|
Net periodic benefit cost for the frozen defined benefit pension plan prior to termination2 |
|
— |
|
|
|
0.7 |
|
|
|
— |
|
|
|
8.4 |
|
Pension settlement loss2 |
|
— |
|
|
|
31.0 |
|
|
|
— |
|
|
|
51.0 |
|
|
|
10.4 |
|
|
|
— |
|
|
|
10.4 |
|
|
|
27.0 |
|
Net income (loss) from ongoing operations1 |
|
2.0 |
|
|
|
1.1 |
|
|
|
17.2 |
|
|
|
(2.0 |
) |
Depreciation and amortization |
|
5.6 |
|
|
|
6.0 |
|
|
|
23.2 |
|
|
|
24.8 |
|
Stock option-based compensation costs |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
0.2 |
|
Interest expense |
|
1.1 |
|
|
|
2.2 |
|
|
|
4.7 |
|
|
|
6.3 |
|
Interest income |
|
— |
|
|
|
(0.4 |
) |
|
|
— |
|
|
|
(0.5 |
) |
Income taxes from ongoing operations1 |
|
2.4 |
|
|
|
(1.0 |
) |
|
|
5.4 |
|
|
|
1.5 |
|
Consolidated EBITDA from ongoing operations |
$ |
11.1 |
|
|
$ |
7.9 |
|
|
$ |
50.5 |
|
|
$ |
30.3 |
|
1. Reconciliations of the pre-tax and post-tax balances attributed to net income (loss) from continuing operations are shown in Note (e). 2. For more information, see Note (h). |
(k) |
In |
|
|
(l) |
The computation of Credit EBITDA, as defined in the ABL Facility, is presented below. |
Computations of Credit EBITDA (as defined in the ABL Facility) as of and for the
Twelve Months Ended |
|||
Computations of Credit EBITDA for the twelve months ended |
|||
Net income (loss) |
$ |
(64,565 |
) |
Plus: |
|
||
After-tax losses related to discontinued operations |
|
65,610 |
|
Total income tax expense for continuing operations |
|
— |
|
Interest expense |
|
4,664 |
|
Depreciation and amortization expense for continuing operations |
|
23,225 |
|
All non-cash losses and expenses, plus cash losses and expenses not to exceed |
|
22,321 |
|
Charges related to stock option grants and awards accounted for under the fair value-based method |
|
— |
|
Losses related to the application of the equity method of accounting |
|
— |
|
Losses related to adjustments in the estimated fair value of assets accounted for under the fair value method of accounting |
|
— |
|
Fees, costs and expenses incurred in connection with the amendment process |
|
459 |
|
Terphane sale transaction costs in an amount not to exceed |
|
— |
|
Minus: |
|
||
After-tax income related to discontinued operations |
|
— |
|
Total income tax benefits for continuing operations |
|
(165 |
) |
Interest income |
|
(36 |
) |
All non-cash gains and income, plus cash gains and income in excess of |
|
— |
|
Income related to changes in estimates for stock option grants and awards accounted for under the fair value-based method |
|
— |
|
Income related to the application of the equity method of accounting |
|
— |
|
Income related to adjustments in the estimated fair value of assets accounted for under the fair value method of accounting |
|
(144 |
) |
Plus cash dividends declared on investments in an amount not to exceed |
|
— |
|
Plus or minus, as applicable, pro forma EBITDA adjustments associated with acquisitions and asset dispositions |
|
— |
|
Plus or minus, as applicable, pro forma EBITDA adjustments to pension expense associated with the early payment of pension obligations |
|
(258 |
) |
Credit EBITDA |
$ |
51,111 |
|
Fixed charge coverage ratio**: |
|
||
Credit EBITDA |
$ |
51,111 |
|
Unfinanced capital expenditures |
$ |
11,858 |
|
Fixed charges |
$ |
5,034 |
|
Fixed charge coverage ratio |
|
7.80 |
|
* Credit EBITDA is not intended to represent net income (loss) or cash flow from operations as defined by GAAP and should not be considered as an alternative to either net income (loss) or to cash flow. ** Fixed Charge Coverage Ratio is computed as the ratio of (a) Credit EBITDA minus Unfinanced Capital Expenditures to (b) Fixed Charges. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20250312893703/en/
Source: